Supplemental Materials for Stein Gold et al. Efficacy and Safety of Apremilast in Patients With Mild-to-Moderate Psoriasis Up to 32 Weeks: Results From the Extension Phase of the Randomized, Phase 3 ADVANCE Trial

Name: Supplemental Materials for Stein Gold et al. Efficacy and Safety of Apremilast in Patients With Mild-to-Moderate Psoriasis Up to 32 Weeks: Results From the Extension Phase of the Randomized, Phase 3 ADVANCE Trial
Creator: Linda Stein Gold
Published: 2022-10-14T18:34:20.648Z
Keywords: Clinical Trial, Scalp, Psoriasis, Quality of Life, Pruritus

Stein Gold, Linda; Papp, Kim; Pariser, David; Bhatia, Neal; Sofen, Howard; Albrecht, Lorne; gooderham, melinda; Callis Duffin, Kristina; Chen, Mindy; Paris, Maria; Cheng, Sue; Picard, Hernan; Wang, Yao; Green, Lawrence

doi:10.17632/wf4g3yxvzz.1

Supplemental Materials for Stein Gold et al. Efficacy and Safety of Apremilast in Patients With Mild-to-Moderate Psoriasis Up to 32 Weeks: Results From the Extension Phase of the Randomized, Phase 3 ADVANCE Trial

Published: 14 October 2022| Version 1 | DOI: 10.17632/wf4g3yxvzz.1

Contributors:

Linda Stein Gold,

,

Description

Mendeley Supplemental Figures for Stein Gold et al. Efficacy and Safety of Apremilast in Patients With Mild-to-Moderate Psoriasis Up to 32 Weeks: Results From the Extension Phase of the Randomized, Phase 3 ADVANCE Trial. J Am Acad Dermatol. 2022.

Supplemental Materials for Stein Gold et al. Efficacy and Safety of Apremilast in Patients With Mild-to-Moderate Psoriasis Up to 32 Weeks: Results From the Extension Phase of the Randomized, Phase 3 ADVANCE Trial

Description

Files

Categories

Licence